litlas
ログインアカウント作成

Aditya Bardia

2006–2025 年に発表

240
論文数
36,310
被引用数
90
h 指数
224
i10 指数

被引用数

Aditya Bardia の年別被引用数1964 年: 被引用 1 件1978 年: 被引用 1 件2005 年: 被引用 2 件2006 年: 被引用 5 件2007 年: 被引用 38 件2008 年: 被引用 42 件2009 年: 被引用 32 件2010 年: 被引用 30 件2011 年: 被引用 36 件2012 年: 被引用 23 件2013 年: 被引用 84 件2014 年: 被引用 142 件2015 年: 被引用 237 件2016 年: 被引用 230 件2017 年: 被引用 301 件2018 年: 被引用 291 件2019 年: 被引用 1,062 件2020 年: 被引用 1,657 件2021 年: 被引用 1,879 件2022 年: 被引用 1,834 件2023 年: 被引用 1,840 件2024 年: 被引用 2,970 件2025 年: 被引用 1,911 件2026 年: 被引用 55 件1965〜1977 年は被引用が無いため表示していません1979〜2004 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,991 件、この内訳の 25.6%中国: 引用元論文 2,147 件、この内訳の 13.8%イタリア: 引用元論文 954 件、この内訳の 6.1%イギリス: 引用元論文 758 件、この内訳の 4.8%ドイツ: 引用元論文 715 件、この内訳の 4.6%フランス: 引用元論文 632 件、この内訳の 4%スペイン: 引用元論文 573 件、この内訳の 3.7%カナダ: 引用元論文 439 件、この内訳の 2.8%オーストラリア: 引用元論文 421 件、この内訳の 2.7%日本: 引用元論文 373 件、この内訳の 2.4%スイス: 引用元論文 354 件、この内訳の 2.3%韓国: 引用元論文 337 件、この内訳の 2.2%
0%25.6%その他 25%

機関

分野

  • Medicine61.5%
  • Biochemistry, Genetics and Molecular Biology29.4%
  • Engineering3.1%
  • Immunology and Microbiology2%
  • Computer Science0.8%
  • Materials Science0.6%
  • その他2.6%

トピック

  • Cancer Cells and Metastasis7.3%
  • Advanced Breast Cancer Therapies6.1%
  • HER2/EGFR in Cancer Research5.6%
  • Cancer Genomics and Diagnostics5%
  • Breast Cancer Treatment Studies4.2%
  • Cancer Immunotherapy and Biomarkers2.4%
  • その他69.4%

共著者

全論文

検索で開く
  1. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    著者: Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert Weaver, Tiffany A. Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Cristiano Ferrario, Peter Schmid, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Hope S. Rugo - New England Journal of Medicine 2021 被引用: 1,543

  2. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

    著者: François‐Clément Bidard, Virginia Kaklamani, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frédéric Forget, Marie‐Ange Mouret‐Reynier, Joohyuk Sohn, Donatienne Taylor, Kathleen Harnden, Hung T. Khong, Judit Kocsis, Florence Dalenc, Patrick M. Dillon, Sunil Babu, Simon Waters, Ines Deleu, José Á. García-Sáenz, Emilio Bria, Marina Elena Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortés, Shubin Liu, Giulia Tonini, Dirk Laurent, Nassir Habboubi, Maureen G. Conlan, Aditya Bardia - Journal of Clinical Oncology 2022 被引用: 695

  3. Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis

    著者: Nicola Aceto, Aditya Bardia, David T. Miyamoto, Maria Donaldson Collier, Ben S. Wittner, Joel A. Spencer, Min Yu, Adam Pely, Amanda Engstrom, Huili Zhu, Brian W. Brannigan, Ravi Kapur, Shannon L. Stott, Toshi Shioda, Sridhar Ramaswamy, David T. Ting, Charles P. Lin, Mehmet Toner, Daniel A. Haber, Shyamala Maheswaran - Cell 2014 被引用: 2,505

  4. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

    著者: Hope S. Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, P. Gómez Pardo, Komal Jhaveri, Rosemary Delaney, T. Valdez, Hao Wang, Monica Motwani, Oh Kyu Yoon, Wendy Verret, Sara M. Tolaney - The Lancet 2023 被引用: 427

  5. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

    著者: Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, Shanu Modi, Aditya Bardia, Sara M. Tolaney, Javier Cortés, Jean‐Charles Soria, Giuseppe Curigliano - CA A Cancer Journal for Clinicians 2021 被引用: 376

  6. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

    著者: Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan, Robert Iannone, Sarah A. Washkowitz, Robert M. Sharkey, William A. Wegener, Kevin Kalinsky - New England Journal of Medicine 2019 被引用: 850

  7. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis

    著者: Laura M. Spring, Geoffrey Fell, Andrea Arfè, Chandni Sharma, Rachel A. Greenup, Kerry L. Reynolds, Barbara L. Smith, Brian M. Alexander, Beverly Moy, Steven J. Isakoff, Giovanni Parmigiani, Lorenzo Trippa, Aditya Bardia - Clinical Cancer Research 2020 被引用: 909

  8. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

    著者: Aditya Bardia, Wells A. Messersmith, Ebenezer A. Kio, Jordan Berlin, Linda T. Vahdat, Gregory A. Masters, R Moroose, Alessandro D. Santin, Kevin Kalinsky, Vincent J. Picozzi, Joyce O’Shaughnessy, Jhanelle E. Gray, Takefumi Komiya, Joshua M. Lang, Jenny C. Chang, Alexander Starodub, David M. Goldenberg, Robert M. Sharkey, Pius Maliakal, Q. Hong, William A. Wegener, Trishna Goswami, Allyson J. Ocean - Annals of Oncology 2021 被引用: 375

  9. Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells

    著者: Tanmoy Saha, Chinmayee Dash, Ruparoshni Jayabalan, Sachin Khiste, Arpita Kulkarni, Kiran Kurmi, Jayanta Mondal, Pradip K. Majumder, Aditya Bardia, Hae Lin Jang, Shiladitya Sengupta - Nature Nanotechnology 2021 被引用: 397

  10. Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

    著者: Min Yu, Aditya Bardia, Ben S. Wittner, Shannon L. Stott, Malgorzata E. Smas, David T. Ting, Steven J. Isakoff, Jordan C. Ciciliano, Marissa Wells, Ajay M. Shah, Kyle Concannon, Maria Donaldson Collier, Lecia V. Sequist, Elena F. Brachtel, Dennis C. Sgroi, José Baselga, Sridhar Ramaswamy, Mehmet Toner, Daniel A. Haber, Shyamala Maheswaran - Science 2013 被引用: 2,496

  11. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

    著者: Debu Tripathy, Seock‐Ah Im, Marco Colleoni, Fábio Franke, Aditya Bardia, Nadia Harbeck, Sara A. Hurvitz, Louis W.C. Chow, Joohyuk Sohn, Keun Seok Lee, Saúl Campos-Gómez, Rafael Villanueva-Vázquez, Kyung Hae Jung, Govind Babu, Paul Wheatley‐Price, Michelino De Laurentiis, Young‐Hyuck Im, Sherko Küemmel, Nagi S. El-Saghir, Mei-Ching Liu, Gary P. Carlson, Gareth Hughes, Iván Díaz-Padilla, Caroline Germa, Samit Hirawat, Yen‐Shen Lu - The Lancet Oncology 2018 被引用: 1,011

  12. Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    著者: Hope S. Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, P. Gómez Pardo, Komal Jhaveri, Rosemary Delaney, Olivia Fu, Lanjia Lin, Wendy Verret, Sara M. Tolaney - Journal of Clinical Oncology 2022 被引用: 298

  13. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

    著者: Aditya Bardia, Xichun Hu, Rebecca Dent, Kan Yonemori, Carlos H. Barrios, Joyce O’Shaughnessy, Hans Wildiers, Jean‐Yves Pierga, Qingyuan Zhang, Cristina Saura, Laura Biganzoli, Joohyuk Sohn, Seock‐Ah Im, Christelle Lévy, William Jacot, Natasha Begbie, Jun Ke, Gargi Patel, Giuseppe Curigliano - New England Journal of Medicine 2024 被引用: 393

  14. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

    著者: Seock‐Ah Im, Yen‐Shen Lu, Aditya Bardia, Nadia Harbeck, Marco Colleoni, Fábio Franke, Louis W.C. Chow, Joohyuk Sohn, Keun-Seok Lee, Saúl Campos-Gómez, Rafael Villanueva-Vázquez, Kyung-Hae Jung, Arunava Chakravartty, Gareth Hughes, Ioannis Gounaris, Karen Rodriguez-Lorenc, Tetiana Taran, Sara A. Hurvitz, Debu Tripathy - New England Journal of Medicine 2019 被引用: 1,021

  15. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer

    著者: Jamie O. Brett, Laura M. Spring, Aditya Bardia, Seth A. Wander - Breast Cancer Research 2021 被引用: 412

  16. Ribociclib plus Endocrine Therapy in Early Breast Cancer

    著者: Dennis J. Slamon, Oleg Lipatov, Zbigniew Nowecki, Nicholas P. McAndrew, Bożena Kukiełka-Budny, Daniil Stroyakovskiy, Denise A. Yardley, Chiun‐Sheng Huang, Peter A. Fasching, John Crown, Aditya Bardia, Stephen Chia, Seock‐Ah Im, Manuel Ruíz-Borrego, Sherene Loi, Binghe Xu, Sara A. Hurvitz, Carlos H. Barrios, Michael Untch, Rebecca Moroose, F. Visco, Karen Afenjar, Rodrigo Fresco, Irene Severin, Yan Ji, Farhat Ghaznawi, Zheng Li, Juan Pablo Zarate, Arunava Chakravartty, Tetiana Taran, Gabriel N. Hortobágyi - New England Journal of Medicine 2024 被引用: 357

  17. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer

    著者: James T. Coates, Sheng Sun, Ignaty Leshchiner, Nayana Thimmiah, Elizabeth E. Martin, Daniel E. McLoughlin, Brian P. Danysh, Kara Slowik, Raquel A. Jacobs, Kahn Rhrissorrakrai, Filippo Utro, Chaya Levovitz, Elyssa N. Denault, Charlotte S. Walmsley, Avinash Kambadakone, James R. Stone, Steven J. Isakoff, Laxmi Parida, Dejan Juric, Gad Getz, Aditya Bardia, Leif W. Ellisen - Cancer Discovery 2021 被引用: 223

  18. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

    著者: Aditya Bardia, Sara M. Tolaney, Kevin Punie, Delphine Loirat, Mafalda Oliveira, Kevin Kalinsky, Amelia Zelnak, Philippe Aftimos, Florence Dalenc, Sagar Sardesai, Erika Hamilton, Priyanka Sharma, Sabela Recalde, Eva Ciruelos Gil, T Traina, Joyce O’Shaughnessy, Javier Cortés, Mu‐Hung Tsai, Linda T. Vahdat, Véronique Dièras, Lisa A. Carey, Hope S. Rugo, David M. Goldenberg, Q. Hong, Martin Olivo, Loretta M. Itri, Sara A. Hurvitz - Annals of Oncology 2021 被引用: 299

  19. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

    著者: Otto Metzger, Giuseppe Viale, Shayna Stein, Lorenzo Trippa, Denise A. Yardley, Ingrid A. Mayer, Vandana G. Abramson, Carlos L. Arteaga, Laura M. Spring, Adrienne G. Waks, Eileen Wrabel, Michelle K. DeMeo, Aditya Bardia, Patrizia Dell’Orto, Leila Russo, Tari A. King, Kornélia Polyák, Franziska Michor, Eric P. Winer, Ian E. Krop - Cancer Discovery 2021 被引用: 240

  20. LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer

    著者: Fátima Cardoso, Heather L. McArthur, Peter Schmid, Javier Cortés, Nadia Harbeck, Melinda L. Telli, David W. Cescon, Joyce O’Shaughnessy, Peter A. Fasching, Zhi-Min Shao, Delphine Loirat, Y.H. Park, María Ángeles Fernández, Z. Liu, Hiroyuki Yasojima, Yu Ding, L. Jia, Vassiliki Karantza, Konstantinos Tryfonidis, Aditya Bardia - Annals of Oncology 2023 被引用: 134

  21. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

    著者: Laura M. Spring, Seth A. Wander, Fabrice André, Beverly Moy, Nicholas C. Turner, Aditya Bardia - The Lancet 2020 被引用: 466

  22. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

    著者: Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Fatima Cardoso, Nadia Harbeck, Sara Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael Villanueva Vazquez, Kyung Hae Jung, K. Govind Babu, Paul Wheatley-Price, Michelino De Laurentiis, Young-Hyuck Im, Sherko Kuemmel, Nagi El-Saghir, Ruth O'Regan, Claudia Gasch, Nadia Solovieff, Craig Wang, Yongyu Wang, Arunava Chakravartty, Yan Ji, Debu Tripathy - Clinical Cancer Research 2021 被引用: 263

  23. Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis

    著者: Richard Y. Ebright, Sooncheol Lee, Ben S. Wittner, Kira Niederhoffer, Benjamin Nicholson, Aditya Bardia, Samuel S. Truesdell, Devon F. Wiley, Benjamin Wesley, Selena S. Li, Andy Mai, Nicola Aceto, Nicole Vincent-Jordan, Annamária Szabolcs, Brian Chirn, Johannes Kreuzer, Valentine Comaills, Mark Kalinich, Wilhelm Haas, David T. Ting, Mehmet Toner, Shobha Vasudevan, Daniel A. Haber, Shyamala Maheswaran, Douglas S. Micalizzi - Science 2020 被引用: 377

  24. Mechanisms of Resistance to Antibody–Drug Conjugates

    著者: Rachel O. Abelman, Bogang Wu, Laura M. Spring, Leif W. Ellisen, Aditya Bardia - Cancers 2023 被引用: 137